Is there any scenario where you would consider treating a relapsed AYA patient with Hodgkin Lymphoma without consolidative auto transplant?   

Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in five-year survival exceeding 90%, even for high risk patients 1. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDCT/ASCT) is standard for adults with first relapse or refra...